John Timothy Greenamyre
#130,053
Most Influential Person Now
John Timothy Greenamyre's AcademicInfluence.com Rankings
John Timothy Greenamyrephilosophy Degrees
Philosophy
#6283
World Rank
#9291
Historical Rank
Logic
#3462
World Rank
#4621
Historical Rank
John Timothy Greenamyrebiology Degrees
Biology
#8518
World Rank
#11609
Historical Rank
Neuroscience
#1180
World Rank
#1222
Historical Rank
Download Badge
Philosophy Biology
John Timothy Greenamyre's Degrees
- PhD Neuroscience University of California, Berkeley
- Doctorate Medicine Stanford University
Why Is John Timothy Greenamyre Influential?
(Suggest an Edit or Addition)John Timothy Greenamyre's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Chronic systemic pesticide exposure reproduces features of Parkinson's disease (2000) (3501)
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines (2002) (1008)
- Mechanism of Toxicity in Rotenone Models of Parkinson's Disease (2003) (926)
- Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation (2003) (719)
- A highly reproducible rotenone model of Parkinson's disease (2009) (632)
- An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage (2002) (584)
- Alternative excitotoxic hypotheses (1992) (565)
- Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization (1999) (538)
- Excitatory amino acids and Alzheimer's disease (1989) (489)
- Mitochondrial dysfunction in Parkinson's disease. (1999) (464)
- N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking (2008) (398)
- Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites. (1985) (375)
- α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease (2016) (365)
- Animal models of Parkinson's disease. (2002) (357)
- Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system (1984) (353)
- Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. (1985) (348)
- Parkinson's--Divergent Causes, Convergent Mechanisms (2004) (348)
- Glutamate dysfunction in Alzheimer's disease: an hypothesis (1987) (342)
- Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives (2014) (338)
- Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system (2006) (333)
- LRRK2 activation in idiopathic Parkinson’s disease (2018) (332)
- Complex I and Parkinson's Disease (2001) (329)
- The role of environmental exposures in neurodegeneration and neurodegenerative diseases. (2011) (312)
- Selective microglial activation in the rat rotenone model of Parkinson's disease (2003) (295)
- Dementia of the Alzheimer's Type: Changes in Hippocampal L‐[3H]Glutamate Binding (1987) (294)
- Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson’s disease (2007) (282)
- Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. (2005) (274)
- Dopaminergic Neurons Intrinsic to the Primate Striatum (1997) (262)
- PCR based determination of mitochondrial DNA copy number in multiple species. (2015) (258)
- Paraquat neurotoxicity is distinct from that of MPTP and rotenone. (2005) (256)
- Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity (2000) (254)
- Environment, Mitochondria, and Parkinson's Disease (2002) (250)
- The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine‐depleted rats and MPTP‐treated monkeys (1991) (249)
- Anatomy and physiology of glutamate in the CNS (1994) (246)
- LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction (2014) (240)
- Ubiquitin–proteasome system and Parkinson's diseases (2005) (231)
- The rotenone model of Parkinson's disease: genes, environment and mitochondria. (2003) (226)
- Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum (1993) (218)
- Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology (2009) (211)
- Glutamate and Parkinson’s disease (1996) (207)
- Toxin models of mitochondrial dysfunction in Parkinson's disease. (2012) (201)
- Role of External Pallidal Segment in Primate Parkinsonism: Comparison of the Effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism and Lesions of the External Pallidal Segment (2004) (197)
- Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. (1998) (193)
- Rotenone Model of Parkinson Disease (2005) (184)
- Biomedicine. Parkinson's--divergent causes, convergent mechanisms. (2004) (184)
- Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism (2005) (183)
- Glutamate transmission and toxicity in alzheimer's disease (1988) (177)
- Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. (2004) (169)
- Neurotoxic in vivo models of Parkinson's disease recent advances. (2010) (168)
- Mitochondrial iron metabolism and its role in neurodegeneration. (2010) (162)
- A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease (2009) (157)
- Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease (1994) (154)
- In Vivo Labeling of Mitochondrial Complex I (NADH:UbiquinoneOxidoreductase) in Rat Brain Using [3H]Dihydrorotenone (2000) (151)
- Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease (2014) (151)
- Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases (2019) (146)
- Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential (1995) (146)
- Bioenergetics and glutamate excitotoxicity (1996) (145)
- Gene–environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models (2013) (143)
- Mechanistic Approaches to Parkinson's Disease Pathogenesis (2002) (142)
- Peroxiredoxin-2 Protects against 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration via Attenuation of the Apoptosis Signal-Regulating Kinase (ASK1) Signaling Cascade (2011) (139)
- Characterization of the Excitotoxic Potential of the Reversible Succinate Dehydrogenase Inhibitor Malonate (1995) (132)
- Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl- d -Aspartate Receptors (2000) (130)
- Lessons from the rotenone model of Parkinson's disease. (2010) (128)
- Species- and tissue-specific relationships between mitochondrial permeability transition and generation of ROS in brain and liver mitochondria of rats and mice. (2007) (127)
- Post-translational modification of α-synuclein in Parkinson׳s disease (2015) (126)
- shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. (2015) (124)
- High correlation between the localization of [3H]TCP binding and NMDA receptors. (1986) (122)
- Ethyl-EPA in Huntington disease (2005) (119)
- Visualization of NMDA Receptor-Induced Mitochondrial Calcium Accumulation in Striatal Neurons (1998) (114)
- A controlled trial of remacemide hydrochloride in Huntington's disease (1996) (111)
- Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (2007) (109)
- In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. (2003) (108)
- Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. (1990) (107)
- Protection by the NDI1 Gene against Neurodegeneration in a Rotenone Rat Model of Parkinson's Disease (2008) (105)
- Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys (2007) (101)
- Synaptic localization of striatal NMDA, quisqualate and kainate receptors (1989) (95)
- Glutamatergic influences on the basal ganglia. (2001) (94)
- Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington’s disease individuals (2005) (93)
- [3H]Dihydrorotenone Binding to NADH: Ubiquinone Reductase (Complex I) of the Electron Transport Chain: An Autoradiographic Study (1996) (91)
- N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. (1991) (89)
- Peroxidase Mechanism of Lipid-dependent Cross-linking of Synuclein with Cytochrome c (2009) (86)
- 3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms (1998) (84)
- Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model (2010) (83)
- Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production (2017) (83)
- Pilocapine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms (2011) (83)
- Autoradiographic localization of cerebellar excitatory amino acid binding sites in the mouse (1987) (82)
- Bacterial spore heat resistance correlated with water content, wet density, and protoplast/sporoplast volume ratio (1982) (82)
- Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease (2014) (80)
- Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling (2010) (74)
- Exacerbation of NMDA, AMPA, and l‐Glutamate Excitotoxicity by the Succinate Dehydrogenase Inhibitor Malonate (1995) (72)
- The role of glutamate in the pathophysiology of Parkinson's disease. (1996) (71)
- Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease (2005) (70)
- Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. (1991) (70)
- Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (2001) (69)
- Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment (2013) (69)
- Hypokinesia and Reduced Dopamine Levels in Zebrafish Lacking β- and γ1-Synucleins* (2011) (68)
- The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum (1994) (67)
- Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. (2008) (67)
- Glutamate recognition sites in human fetal brain (1988) (66)
- Subthalamic Ablation Reverses Changes in Basal Ganglia Oxidative Metabolism and Motor Response to Apomorphine Induced by Nigrostriatal Lesion in Rats (1997) (66)
- GluR1 Glutamate Receptor Subunit Is Regulated Differentially in the Primate Basal Ganglia Following Nigrostriatal Dopamine Denervation (2000) (65)
- Advances in Neurology, vol 53, Parkinson's Disease: Anatomy, Pathology, and Therapy (1991) (65)
- Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. (2011) (65)
- LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease (2017) (64)
- RAD52 is required for RNA-templated recombination repair in post-mitotic neurons (2017) (63)
- Pathogenesis of Parkinson's disease. (2001) (62)
- Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria. (2004) (60)
- LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease (2015) (59)
- Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. (2011) (59)
- DJ-1 Expression Modulates Astrocyte-Mediated Protection Against Neuronal Oxidative Stress (2013) (58)
- Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra (2011) (56)
- Rotenone Model of Parkinson Disease MULTIPLEBRAINMITOCHONDRIADYSFUNCTIONSAFTERSHORTTERMSYSTEMIC ROTENONEINTOXICATION (2005) (55)
- LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease (2019) (55)
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
- Manipulation of Membrane Potential Modulates Malonate‐Induced Striatal Excitotoxicity In Vivo (1996) (52)
- NeuN is not a reliable marker of dopamine neurons in rat substantia nigra (2009) (51)
- Thiol oxidation and altered NR2B/NMDA receptor functions in in vitro and in vivo pilocarpine models: Implications for epileptogenesis (2013) (46)
- Quantitative autoradiography of L-[3H]glutamate binding to rat brain (1983) (46)
- Rotenone Model of Parkinson’s Disease: Multiple Brain Mitochondria Dysfunctions after Short-term Systemic Rotenone Intoxication (2005) (46)
- Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. (2012) (46)
- Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro (2013) (45)
- Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer (2016) (44)
- Lead-induced changes in NMDA receptor complex binding: correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA administration (1997) (42)
- Quantitative Autoradiography of Dihydrorotenone Binding to Complex I of the Electron Transport Chain (1992) (42)
- Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats (2015) (41)
- Selective vulnerability of the CA1 region of hippocampus to the indirect excitotoxic effects of malonic acid (1995) (40)
- Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat (1995) (40)
- Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP (2004) (39)
- Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease (2004) (37)
- Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats (2015) (37)
- Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease: “Use it and lose it” (1991) (35)
- Sodium-dependentd-aspartate ‘binding’ is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay (1990) (35)
- Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease. (2011) (34)
- Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress (2018) (32)
- Sex Differences in Rotenone Sensitivity Reflect the Male-to-Female Ratio in Human Parkinson's Disease Incidence. (2019) (31)
- Oxidative damage in Parkinson's disease. (2005) (30)
- A FRET-based method to study protein thiol oxidation in histological preparations. (2008) (30)
- LRRK2 and idiopathic Parkinson’s disease (2022) (29)
- Neurotransmitter receptors in Alzheimer disease. (1993) (29)
- Differential Expression of Glutamate Receptors by the Dopaminergic Neurons of the Primate Striatum (1999) (29)
- Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents (2010) (29)
- Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. (2002) (29)
- Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration (2019) (28)
- Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells. (2006) (28)
- Regional ontogeny of a unique glutamate recognition site in rat brain: An autoradiographic study (1990) (28)
- Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia (1995) (28)
- Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK-801 (1995) (28)
- Editor’s Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinson’s Disease Risk (2017) (27)
- Phenothiazine normalizes the NADH/NAD+ ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of Parkinson's disease (2019) (26)
- New Frontiers in Parkinson's Disease: From Genetics to the Clinic (2018) (26)
- Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions (2001) (26)
- Huntington's disease--making connections. (2007) (25)
- Immunocytochemical Characterization of the Mitochondrially Encoded ND1 Subunit of Complex I (NADH : Ubiquinone Oxidoreductase) in Rat Brain (2000) (24)
- Ca2+‐Dependent Permeability Transition and Complex I Activity in Lymphoblast Mitochondria from Normal Individuals and Patients with Huntington's or Alzheimer's Disease (1999) (22)
- ARL-15896, a NovelN-Methyl-D-aspartate Receptor Ion Channel Antagonist: Neuroprotection against Mitochondrial Metabolic Toxicity and Regional Pharmacology (1996) (22)
- Parkinson's disease: animal models. (2007) (22)
- The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability (2022) (21)
- Mitochondrial DNA damage as a peripheral biomarker for mitochondrial toxin exposure in rats. (2014) (21)
- Regional variations in the pharmacology of AMPA receptors as revealed by receptor autoradiography (1994) (20)
- Response: Parkinson's disease, pesticides and mitochondrial dysfunction (2001) (20)
- Protective and symptomatic strategies for therapy of Parkinson's disease. (1999) (19)
- Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease. (2018) (19)
- α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo (2020) (19)
- Neurodegenerative disease: Pink, parkin and the brain (2006) (19)
- Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease (2020) (18)
- Mouse ES cells overexpressing DNMT1 produce abnormal neurons with upregulated NMDA/NR1 subunit. (2011) (18)
- Photometric immersion refractometry of bacterial spores (1982) (18)
- Ca(2+)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease. (1999) (17)
- Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion (1995) (17)
- Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease (2011) (17)
- Intrastriatal Neurotoxin Injections Reduce in Vitro and in Vivo Binding of Radiolabeled Rotenoids to Mitochondrial Complex I (1997) (17)
- A Rapid and Sensitive Automated Image‐Based Approach for In Vitro and In Vivo Characterization of Cell Morphology and Quantification of Cell Number and Neurite Architecture (2014) (17)
- A study of cortical and hippocampal NMDA and PCP receptors following selective cortical and subcortical lesions (1991) (16)
- Pharmacological pallidotomy with glutamate antagonists? (1996) (15)
- NMDA and AMPA Receptors in Transgenic Mice Expressing Human β‐Amyloid Protein (1993) (15)
- Update on huntington’s disease (2006) (15)
- We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? (2002) (14)
- Spectrum of Tau Pathologies in Huntington’s disease (2018) (14)
- Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates (2004) (13)
- Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease. (2020) (12)
- Preventing Parkinson’s Disease: An Environmental Agenda (2021) (12)
- A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic? (2001) (12)
- Synthesis and evaluation of a new fluorine-18 labeled rotenoid as a potential PET probe of mitochondrial complex I activity (1999) (12)
- Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20 (2020) (11)
- LRRK 2 G 2019 S-induced mitochondrial DNA damage is LRRK 2 kinase dependent and inhibition restores mtDNA integrity in Parkinson ’ s disease (2017) (11)
- Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism (2008) (11)
- Susceptibility of adult rats to lead-induced changes in NMDA receptor complex function. (1997) (10)
- Pesticides and Parkinson’s Disease (2001) (10)
- Assay of [3H]dihydrorotenone binding to complex I in intact human platelets. (1995) (10)
- "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology. (2000) (10)
- Transient muscarinic and glutamatergic stimulation of neural stem cells triggers acute and persistent changes in differentiation (2014) (9)
- Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to age‐related neurodegeneration (2021) (9)
- Bioenergetics and excitotoxicity: The weak excitotoxic hypothesis (1996) (8)
- NADPH oxidase 2 activity in Parkinson’s disease (2022) (8)
- The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease (2021) (8)
- Inhibition of autoradiographic MK-801 binding by an endogenous factor (1994) (8)
- VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration (2021) (8)
- Protection by the NDI 1 Gene against Neurodegeneration in a Rotenone Rat Model of Parkinson ’ s Disease (2008) (8)
- Contamination of commercially available quisqualic acid by glutamate-like and aspartate-like substances (1989) (8)
- Newly Revised Quantitative PCR‐Based Assay for Mitochondrial and Nuclear DNA Damage (2018) (8)
- Fruit flies, bile acids, and Parkinson disease (2015) (8)
- What's wrong with mitochondria in Parkinson's disease? (2018) (7)
- Autoradiographic analysis of L-3H-glutamate receptors in mammalian brain (1986) (7)
- NMDA and AMPA receptors in transgenic mice expressing human beta-amyloid protein. (1993) (6)
- Authors' response to commentaries (1989) (5)
- The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson’s disease (2020) (5)
- Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20 (2020) (4)
- Rotenone as Preclinical Model Compound in Parkinson Disease (2014) (4)
- Huntington's disease: getting closer. (2007) (4)
- Reply from W.F. Maragos and colleagues (1987) (4)
- A therapeutic target and biomarker in Friedreich's ataxia. (2000) (4)
- Regulation of complex I by Engrailed is complex too (2011) (3)
- Complex I Inhibition, Rotenone and Parkinson's Disease (2008) (3)
- Blockade of Cannabinoid CB 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in MPTP-Treated Rhesus Monkeys (2007) (3)
- CHAPTER 1:Etiology and Pathogenesis of Parkinson’s Disease (2017) (2)
- CHAPTER B4 – Rotenone Rat and Other Neurotoxin Models of Parkinson Disease (2005) (2)
- Genetic Factors in Environmentally Induced Disease (2015) (2)
- Critical Review Complex I and Parkinson's Disease (2001) (2)
- Chronic treatment with thioctic acid does not protect against malonate toxicity in vivo (1995) (1)
- Disulfide bridge formation prevents CaMKII/Calmodulin interaction in Parkinson’s disease (2020) (1)
- In Memoriam: Samay Jain (2017) (1)
- VGLUT modulates sex differences in dopamine neuron vulnerability to age-related neurodegeneration (2020) (1)
- Response to Rotenone and Parkinson's disease; reduced sensitivity in females. (2019) (1)
- Mouse ES cells overexpressing DNMT1 produce abnormal neurons with upregulated NR1 (2011) (1)
- Spectrophotometric determination of refractive index increment for bacterial cells (1990) (1)
- QUANTITATIVE A U T O ~ D I O G ~ H Y OF L-I3HIGLUTAMATE BINDING TO RAT BRAIN (2002) (0)
- Samay Jain, MD, June 2, 1974-September 8, 2016. (2016) (0)
- T1782 Rotenone Recapitulates Parkinson's Disease-Related Gastrointestinal Motility Deficits and Alpha-Synuclein Pathology in the Enteric Nervous System (2009) (0)
- Editorial Board (2008) (0)
- Speaker abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
- Chronic Complex I Inhibition Reproduces Features of Parkinson’s Disease (2002) (0)
- Corrigendum to “Transient muscarinic and glutamatergic stimulation of neural stem cells triggers acute and persistent changes in differentiation” [Neurobiol. Dis. 70 (2014) 252–261] (2014) (0)
- Symposium S20: Environmental and Genetic Interactions (2004) (0)
- Autoradiographic Characterization Of L-(tritium)glutamate Binding Sites In The Central Nervous System (receptors, Nmda, Kainate, Quisqualate). (1986) (0)
- DJ-1 Expression Modulates Astrocyte-Mediated Protection Against Neuronal Oxidative Stress (2012) (0)
- Prospects of Glutamate Antagonists for PD Therapy (2002) (0)
- Recent developments in the cause and treatment of movement disorders: Editorial overview (1994) (0)
- Synuclein-Mitochondrial Interactions in Substantia Nigra Dopamine Neurons (2014) (0)
- Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production (2017) (0)
- Bacterial Spore HeatResistance Correlated withWater Content, WetDensity, andProtoplast/Sporo plast Volume Ratiot (1982) (0)
- Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease (2020) (0)
- 335P (1995) (0)
- Phospholipase iPLA 2 Averts Ferroptosis by Eliminating Death Signal, 15HpETE-PE: Relevance to Parkinson’s Disease (2021) (0)
- Behavioral, neurochemical, and pathological alterations in BAC transgenic G2019S LRRK2 rats (2017) (0)
- Editorial (2005) (0)
- The Gordon Research Seminar & Conference on Parkinson’s disease: state of the Science 200 years after James Parkinson’s essay on the Shaking Palsy (2017) (0)
- Editorial Board (2011) (0)
- Excitotoxicity in Parkinson’s Disease (2004) (0)
- Editorial Board (2008) (0)
- mice in brain and liver mitochondria of rats and mitochondrial permeability transition and generation Species- and tissue-specific relationships between (2007) (0)
- 183. Neuroleptic effects on the respiratory chain (1996) (0)
- Neuroprotective actions of a fatty acid nitroalkene in Parkinson’s disease (2023) (0)
- REGIONAL ONTOGENY OF A UNIQUE GLUTA~A~ R~COGNI~O~ SITE IN RAT BRAIN: AN AUTORA~IOGRA~H~C (1990) (0)
- Short hairpin RNA targeting endogenous alpha-synuclein prevents degeneration of dopaminergic neurons in the rat rotenone model of Parkinson's disease (S7.007) (2015) (0)
- QUANTITATIVE AUTO~DIOG~HY OF L-I3HIGLUTAMATE BINDING TO RAT BRAIN (1983) (0)
- Neurodegenerative Diseases: Mitochondria, metabolic inhibitors and neurodegeneration (2005) (0)
- Growth, impact factor and change at Neurobiology of Disease (2007) (0)
- Speaker abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
- 335P Evaluation of the Glutamate Antagonist Remacemide Hydrochloride in Huntington's Disease (1995) (0)
- Faculty Opinions recommendation of Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. (2017) (0)
- Neuronal NADPH oxidase 2 in Parkinson’s disease pathogenesis (2021) (0)
- Rotenone Model for Parkinson’s Disease (2007) (0)
- Glutamate Receptors and Glutamate Corticofugal Pathways (1986) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John Timothy Greenamyre?
John Timothy Greenamyre is affiliated with the following schools:
